Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new positive efficacy, safety and ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

Despite the challenges, many individuals with schizophrenia can lead fulfilling lives with the right treatment and support.

Data from the federal government shows that Mississippi consistently ranks in the top five in the nation for its rates of ...

A new study in the Journal of Child and Adolescent Psychopharmacology estimates the incidence of neuroleptic malignant ...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word (s): Half Year Results Newron presents H1 2024 results and provides business update 19.09.2024 / 07:00 CET/CEST The issuer is solely responsible ...

The use of antipsychotics for schizophrenia was associated with higher risk for severe cases of COVID-19 and non–COVID-19 respiratory infections but not mild infection.

Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.

The following is a summary of “Antipsychotic exposure and infection risk in people with schizophrenia spectrum disorders ...

In the complex landscape of mental health research, a new viewpoint offers a critical examination of how genes and ...

Certain risk factors and drugs may raise ... be ones also implicated in schizophrenia, said Lauriello. Some research has identified gene polymorphisms involving antipsychotic metabolism and ...

MONTREAL, Sept. 4, 2024 /CNW/ - AbbVie (NYSE: ABBV) today announced that Canada’s Drug Agency (CDA, formerly CADTH) has recommended that VRAYLAR be reimbursed with conditions, for the treatment of ...